Aldeyra Therapeutics, Inc. (ALDX)
| Market Cap | 95.99M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -33.85M |
| Shares Out | 60.18M |
| EPS (ttm) | -0.56 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 491,039 |
| Open | 1.570 |
| Previous Close | 1.580 |
| Day's Range | 1.560 - 1.620 |
| 52-Week Range | 1.070 - 6.175 |
| Beta | 1.33 |
| Analysts | Buy |
| Price Target | 5.50 (+244.83%) |
| Earnings Date | May 13, 2026 |
About ALDX
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for ALDX stock is "Buy." The 12-month stock price target is $5.5, which is an increase of 244.83% from the latest price.
News
ALDX INVESTOR REMINDER: Aldeyra Therapeutics, Inc. Investors Have Until May 29, 2026 To Seek Lead Plaintiff Role
NEW YORK--(BUSINESS WIRE)--If you have suffered a loss on your Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ:ALDX) investment, contact Lauren Molinaro of Kirby McInerney LLP by email...
ADLX Stockholders Have Rights – If You Lost Money Investing in Aldeyra Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses
SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aldeyra Therapeutics, Inc. (...
Bragar Eagel & Squire, P.C. Encourages Aldeyra Therapeutics, Inc. Investors to Contact the Firm Regarding Their Rights
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Aldeyra (ALDX) To Contact Him Directly To Discuss Their Options
Shareholders who lost money in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) Should Contact Wolf Haldenstein Immediately
Lead Plaintiff Deadline is May 29, 2026 NEW YORK, April 7, 2026 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP informs investors that a securities fraud class action lawsuit has been filed ...
$ALDX Lawsuit: Aldeyra Therapeutics, Inc. Sued for Securities Fraud; Investors Should Contact Block & Leviton to Possibly Recover Losses
A securities fraud lawsuit has been filed against Aldeyra Therapeutics (Nasdaq: ALDX). Investors who lost money in ALDX should contact Block & Leviton.
What's Going On With Aldeyra Therapeutics Stock On Thursday?
Since Tuesday, the company's stock has slumped by around 67%.
Aldeyra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
San Diego, California--(Newsfile Corp. - March 17, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Aldeyra Therapeutics (NASDAQ: ALDX). The investigation focus...
US FDA declines to approve Aldeyra's drug for eye disorder
The U.S. Food and Drug Administration on Tuesday declined to approve Aldeyra Therapeutics' drug for a type of eye disease, the company said.
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...
Aldeyra Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Reproxalap is nearing a key FDA decision for dry eye disease, with potential to uniquely address both dry eye and allergic conjunctivitis. Strategic collaboration with AbbVie could bring significant financial milestones and commercial strength.
Aldeyra Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...
Aldeyra Therapeutics Transcript: Study Update
The FDA extended the PDUFA date for reproxalap's NDA after requesting a field trial CSR, despite prior agreement to omit it. The review is nearly complete, and labeling discussions are underway, with a decision expected by February 2026. The AbbVie partnership terms remain unchanged.
Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...
Aldeyra Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
A major regulatory decision for Reproxalap in dry eye disease is expected in December, with a lucrative AbbVie partnership pending approval. The drug’s rapid onset and anti-redness features set it apart, and late-stage data support expansion into allergic conjunctivitis.
Aldeyra Therapeutics Transcript: Jefferies London Healthcare Conference 2025
A major FDA decision for a dry eye therapy is expected in December, with strong clinical data and commercial plans in place, including a significant partnership with AbbVie. The pipeline includes late-stage and preclinical programs targeting ocular, dermatological, and neurological diseases.
Aldeyra Therapeutics Transcript: R&D Day 2025
RASP modulation platform is expanding into CNS and immune-mediated diseases, with ADX-248 showing strong preclinical efficacy and reproxalap advancing toward potential FDA approval. Financial runway extends into 2027, and key regulatory and manufacturing milestones have been met.
Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...
Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ET
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated dise...
Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...
4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals
Among the recent momentum standouts in the biotechnology sector, four stocks have drawn considerable investor attention, entering the top 10th percentile of momentum-ranked stocks based on decisive we...
Aldeyra Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Reproxalap is approaching a key PDUFA date with rapid-onset efficacy and unique label advantages, while AbbVie may exercise a lucrative option. The pipeline features pivotal trials for ocular lymphoma and novel oral therapies for atopic dermatitis, with multiple catalysts expected through 2026.
Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...
Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the European Medicines Agency (EMA) has granted Orphan Designation for ADX-2191 (methotrexat...
Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for ADX-2191 ...